Biotechs’ Best Friend Celgene Sees Deal Strategy Put to Test
This article is for subscribers only.
Celgene Corp.’s head of dealmaking, George Golumbeski, has bet more heavily on partnerships with biotech startups than any of the drugmaker’s rivals. He’s about to find out if the strategy pays off.
Under Golumbeski, the drugmaker has struck more licensing deals than any other biotech company -- 10 in 2014, according to data compiled by Bloomberg Intelligence. It currently has 37 active alliances.